Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $15.71

Shares of Altimmune, Inc. (NASDAQ:ALT) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $15.7143.

Several research analysts have recently commented on the stock. Citigroup restated a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research report on Wednesday, June 24th. Finally, Citizens Jmp cut their target price on Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new position in shares of Altimmune in the 2nd quarter valued at approximately $2,097,000. Hennion & Walsh Asset Management Inc. lifted its holdings in Altimmune by 156.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock worth $1,575,000 after purchasing an additional 316,209 shares during the last quarter. PVG Asset Management Corp acquired a new stake in Altimmune in the 1st quarter worth approximately $204,000. Bank of America Corp DE boosted its position in Altimmune by 48.6% during the first quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock worth $1,756,000 after purchasing an additional 186,420 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in Altimmune by 101.6% during the first quarter. EverSource Wealth Advisors LLC now owns 35,650 shares of the company’s stock worth $110,000 after purchasing an additional 17,967 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Up 2.3%

Shares of NASDAQ ALT opened at $3.08 on Thursday. The business has a 50 day simple moving average of $2.90 and a 200 day simple moving average of $3.46. Altimmune has a 52 week low of $2.56 and a 52 week high of $6.44. The stock has a market cap of $598.97 million, a price-to-earnings ratio of -3.31 and a beta of 0.27. The company has a debt-to-equity ratio of 0.12, a quick ratio of 29.56 and a current ratio of 29.56.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. On average, research analysts predict that Altimmune will post -0.64 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.